Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus nivolumab with chemoradiotherapy followed by surgery in resectable or borderline resectable T3-4N0-1 NSCLC
2019-003454-83Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety, Feasibility and 1 more. Started Dec 2019; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003454-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003454-83.